SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT

Newsfile Corp.
·1 min read

New York, New York--(Newsfile Corp. - April 10, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Osmotica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 30, 2021, Osmotica issued a press release announcing the Company's fourth quarter and full year 2020 financial and operating results. For the quarter, Osmotica reported GAAP earnings per share of $0.88, missing consensus estimates by $0.64, and revenue of $34.53 million, missing estimates by $1.2 million and representing a 42.4% year-to-year decline.

On this news, Osmotica's stock price fell $0.25 per share, or 7.12%, to close at $3.26 per share on March 31, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80071